Clinical Pharmacokinetics of Commonly Used Anticancer Drugs

Alberts, D.S.; Bachur, N.R. and Holtzman, J.L.: The pharmacokinetics of daunomycin in man. Clinical Pharmacology and Therapeutics 12: 96–104 (1971). Alberts, D.S.; Chen, H-S.G.; Chang, S.Y. and Peng, Y.M.: The disposition of intraperitoneal bleomycin, melphalan, and vin-blastine, in cancer patients; in Mathe and Muggia (Eds) Cancer: Chemo- and Immunopharmacology, Recent Results in Cancer Research, 74: 293–299 (Springer-Verlag New York 1980). Alberts, D.S.; Chen, H-S.; Liu, R.; Himmelstein, K.J.; Mayersohn, M.; Perrier, D.; Gross, J.; Moon, T.; Broughton, A. and Salmon, S.E.: Bleomycin pharmacokinetics in man. I. Intravenous administration. Cancer Chemotherapy and Pharmacology 1: 177–181 (1978). Ardalan, B. and Glazer, R.: An update on the biochemistry of 5-fluorouracil. Cancer Treatment Reviews 8: 157–167 (1981). Bachur, N.R.; Riggs, C.E.; Green, M.R.; Langone, J.J.; Van Vunakis, H. and Levin, L.: Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay. Clinical Pharmacology and Therapeutics 21: 70–77 (1977). Bagley, C.M.; Bostich, F.W. and DeVita, V.T.: Clinical pharmacology of cyclophosphamide. Cancer Research 33: 226–233 (1973). Balis, F.M.; Savitch, U.L. and Bleyer, W.A.: Pharmacokinetics of oral methotrexate in children. Cancer Research (In press, 1983). Band, P.R.; Holland, J.F.; Bernard, J.; Weil, M.; Walker, M. and Rail, D.: Treatment of central nervous system leukemia with intrathecal cytosine arabinoside. Cancer 32: 744–748 (1973). Bateman, J.R.; Pugh, R.P.; Cassidy, F.R.; Marshall, G.J. and Irwin, L.E.: 5-fluorouracil given once weekly: Comparison of intravenous and oral administration. Cancer 28: 907–913 (1971). Belt, R.J.; Himmelstein, K.J.; Patton, T.F.; Bannister, S.J.; Sternson, L.A. and Repta, A.J.: Pharmacokinetics of non-proteinbound platinum species following administration of cis-dich-lorodiamminoplatinum (II). Cancer Treatment Reports 63: 1515–1521 (1979). Bender, R.A.; Castle, M.C.; Margileth, D.A. and Oliverio, V.T.: The pharmacokinetics of (3-H)-vincristine in man. Clinical Pharmacology and Therapeutics 22: 430–438 (1977). Bender, R.A.; Zwelling, L.A.: Doroshow, J.H.; Locker, G.Y.; Hande, K.R.; Murinson, D.S.; Cohen, M.; Myers, C.E. and Chabner, B.A.; Antineoplastic drugs: Clinical pharmacology and therapeutic use. Drugs 16: 46–87 (1978). Benjamin, R.S.: Clinical pharmacology of adriamycin (NSC-123127). Cancer Chemotherapy Reports (Part 3) 6: 183–185 (1975). Benjamin, R.S.: Human pharmacology of daunomycin. Cancer Treatment Reports (in press 1982). Benjamin, R.; Legha, S.; Mackay, B.; Ewer, M.; Wallace, S.; Valdivieso, M.; Rasmussen, S.; Blumenschein, G. and Freireich, E.: Reduction of adriamycin cardiac toxichy using a prolonged continuous intravenous infusion. Proceedings of the American Association for Cancer Research 22: 179 (1981). Benjamin, R.S.; Riggs, C.E. and Bachur, N.R.: Pharmacokinetics and metabolism of adriamycin in man. Clinical Pharmacology and Therapeutics 14: 592–600 (1973). Benjamin, R.S.; Riggs, C.E. and Bachur, N.R.: Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Research 37: 1416–1420 (1977). Benjamin, R.S.; Wiernik, P.H. and Bachur, N.R.: Adriamycin chemotherapy — Efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 33: 19–27 (1974). Benz, C. and Cadman, E.: Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. Cancer Research 41: 994–999 (1981). Bern, M.M.; McDerrnott, W.; Cady, B.; Oberfield, R.A.; Trey, C.; Clouse, M.E.; Tullis, J.L. and Parker, L.M.: Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma. Cancer 42: 399–405 (1978). Bertino, J.R.: Toward improved selectivity in cancer chemotherapy: The Richard and Hinda Rosenthal Award Lecture. Cancer Research 39: 293–304 (1979). Bleyer, W.A.: The clinical pharmacology of methotrexate. New applications of an old drug. Cancer 41: 36–51 (1978). Bleyer, W.A.: Therapeutic drug monitoring of methotrexate and other antineoplastic drugs; in Baer and Dito (Eds) Interpretations in Therapeutic Drag Monitoring (American Society of Clinical Pathology Chicago, 1981). Bleyer, W.A. and Poplack, D.G.: Clinical studies on the centralnervous-system pharmacology of methotrexate; in Pinedo and Boelsma (Eds) Clinical Pharmacology of Anti-neoplastic Drugs, pp. 115–131 (Elsevier/North Holland Biomedical Press Amsterdam 1978). Blum, R.H.; Carter, S.K. and Agre, K.: A clinical review of bleomycin - a new antineoplastic agent. Cancer 31: 903–914 (1973). Bono, V.H.: Review of mechanism of action studies of the nitrosoureas. Cancer Treatment Reports 60: 699–702 (1976). Boomla, K.; Aherne, W.; Greaves, M.W.; Davey, R. and Quinton, M.: Radioimmunoassayable methotrexate concentrations in plasma and skin exudate of patients with psoriasis. British Journal of Dermatology 101: 109–110 (1979). Boston Collaborative Drug Surveillance Program: Allopurinol and cytotoxic drugs. Journal of the American Medical Association 227: 1036–1040 (1974). Bourke, R.S.; Chheda, G.; Bremer, A.; Watanabe, O. and Tower, D.B.: Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Research 35: 110–116 (1975). Bramwell, V.; Calvert, R.T.; Edwards, G.; Scarffe, H. and Crowther, D.: The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemotherapy and Pharmacology 3: 253–259 (1979). Bratlid, D. and Moe, P.J.: Pharmacokinetics of high-dose methotrexate treatment in children. European Journal of Clinical Pharmacology 14: 143–147 (1978). Brock, N.; Gross, R.; Hohorst, H.-J.; Klein, H.O. and Schneider, B.: Activation of cyclophosphamide in man and animals. Cancer 27: 1512–1529 (1971). Brock, N.; Stekar, J.; Pohl, J.; Niemeyer, U. and Scheffler, G.: Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sulfosfamide. Arzneimittel-Forschung 29: 659–661 (1979). Cadman, E.; Heimer, R. and Benz, C.: The influence of methotrexate pretreatment on 5-fluorouraeil metabolism in L-1210 cells. Journal of Biological Chemistry 256: 1695–1704 (1981). Calvert, A.H.; Bondy, P.K. and Harrap, K.R.: Some observations on the human pharmacology of methotrexate. Cancer Treatment Reports 61: 1647–1656 (1977). Capizzi, R.L.; Summers, W.P. and Bertmo, J.R.: L-asparaginase induced alteration of amethopterin (methotrexate) activity in mouse leukemia L5178Y. Annals of the New York Academy of Sciences 186: 302–311 (1971). Carter, S.K.: Cyclophosphamide in solid tumors. Cancer Treatment Reviews 2: 295–322 (1975). Carter, S.K.; Bakowski, M.T. and Hellman, K.: Chemotherapy of Cancer (John Wiley & Sons, New York 1977). Carter, S.K.; Schabel, F.M.; Broder, L.E. and Johnston, T.P.: 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) and other nitrosourea in cancer treatment: A review. Advances in Cancer Research 16: 273–332 (1972). Casper, E.S.; Kelsen, D.P.; Alcock, N.W. and Young, C.W.: Platinum concentration in bile and plasma following rapid and 6-hour infusions of cis-dichlorodiammineplatinum (II). Cancer Treatment Reports 63: 2023–2025 (1979). Chabner, B.A.; Myers, C.E. and Oliverio, V.T.: Clinical pharmacology of antineoplastic drugs. Seminars in Oncology 4: 165–191 (1977). Chan, K.K.; Chlebowski, R.T.; Tong, M.; Chen, H-S.G.; Gross, J.F. and Bateman, J.R.: Clinical pharmacokinetics of adria-mycin in hepatoma patients with cirrhosis. Cancer Research 40: 1263–1268 (1980). Christophidis, N.; Vajda, F.J.E. and Lucas, I.; Drummer, O.; Moon, W.J. and Louis, W.J.: Fluorouracil therapy in patients with carcinoma of the large bowel; a pharmacokinetic comparison of various rates and routes of administration. Clinical Pharmacokinetics 3: 330–336 (1978). Chu, M-Y.: Incorporation of arabinosyl cytosine into 2-7S ribonucleic acid and cell death. Biochemical Pharmacology 20: 2057–2063 (1971). Cline, M.J. and Haskell, C.M.: Cancer Chemotherapy [3rd ed.] (W.B. Saunders Company, Philadelphia 1980). Cohen, J.L.; Irwin, L.E.; Marshall, G.J.; Darvey, H. and Bateman, J.R.: Clinical pharmacology of oral and intravenous 5-fluo-rouracil (NSC-19893). Cancer Chemotherapy Reports (Part 1) 58: 723–731 (1974). Cohen, J.L.; Jao, J.Y. and Jusko, W.J.: Pharmacokinetics of cyclophosphamide in man. British Journal of Pharmacology 43: 677–680 (1971). Colvin, M.; Brundrett, R.B.; Cowens, W.; Jardine, I. and Ludlum, D.B.: A chemical basis for the antitumor activity of chloroethylnitrosoureas. Biochemical Pharmacology 25: 695–699 (1976a). Colvin, M.; Brundrett, R.B.; Kan, M-N.N.; Jardine, I. and Fenselau, C.: Alkylating properties of phosphoramide mustard. Cancer Research 36: 1121–1126 (1976b). Colvin, M.; Padgett, C.A. and Fenselau, C.: A biologically active metabolite of cyclophosphamide. Cancer Research 33: 915–918 (1973). Comis, R.L.; Kuppinger, M.S.; Ginsberg, S.J.; Crooke, S.T.; Gilbert, R.; Auchincloss, J.H., and Prestayko, A.W.: Role of singlebreath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Research 39: 5076–5080 (1979). Connors, T.A.; Cox, P.J.; Farmer, P.B.; Foster, A.B. and Jarman, M.: Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophos-phamide. Biochemical Pharmacology 23: 115–129 (1974). Cooper, K.R. and Hong, W.K.: Prospective study of pulmonary toxicity of continuously infused bleomycin. Cancer Treatment Reports 65: 419–425 (1981). Cox, P.J.: Cyclophosphamide cystitis - identification of acolein as the causative agent. Biochemical Pharmacology 28: 2045–2049 (1979). Creasey, W.A.: Vinca alkaloids; in Brodsky et al. (Eds) Cancer Chemotherapy III, pp.49–58 (Grune and Stratton New York 1978). Creasey, W.A.; Papac, R.J.; Markiw, M.E.; Calabresi, P. and Welch, A.D.: Biochemical and pharmacological studies with I-B-D-arabinofuranosylcytosine in man. Biochemical Pharmacology 15: 1417–1428 (1966). Crooke, S.T.; Comis, R.I.; Einhorn, L.H.; Strong, J.E.; Broughton, A. and Prestayko, A.W.: Studies on the clinical pharmacology of bleomycin; in Carter, et al. (Eds) Antitumor Antibiotics, Recent Results in Cancer Research, Vol. 63: 219–229 (Springer-Verlag New York 1978). Crooke, S.T.; Prestayko, A.W. and Strong, J.E.: Recent advances in the study of clinical pharmacology of bleomycin; in Pinedo (Ed.) Clinical Pharmacology of Anti-Neoplastic Drugs, pp. 225–244 (Elsevier North-Holland Biomedical Press, Amsterdam 1978). Davis, H.L. and Davis, T.E.: Daunorubicin and adriamycin in cancer treatment: An analysis of their roles and limitations. Cancer Treatment Reports 63: 809–815 (1979). DeConti, R.C.; Toftness, B.R.; Lange, R.C. and Creasy, W.A.: Clinical and pharmacological studies with cis-diamminedi-chloroplatinum (II). Cancer Research 33: 1310–1315 (1973). DeVita, V.T.; Denham, C.; Davidson, J.D. and Oliverio, V.T.: The physiological disposition of the carcinostatic 1,3-bis (2-chloroethyl)-l-nitrosourea (BCNU) in man and animals. Clinical Pharmacology and Therapeutics 8: 566–577 (1967). Dillaha, C.J.; Jansen, G.T.; Honeycutt, W.M. and Holt, G.A.: Further studies with topical 5-fluorouracil. Archives of Dermatology 92: 410–417 (1965). D’Incalci, M.; Bolis, G.; Facchinetti, T.; Mangioni, C.; Morasca, L.; Morazzoni, P. and Salmona, M.: Decreased half life of cyclophosphamide in patients under continual treatment. European Journal of Cancer 15: 7–10 (1979). Donehower, R.C.; Hande, K.R.; Drake, J.C. and Chabner, B.A.: Presence of 2,4-diamino-N10-methylpteroic acid after highdose methotrexate. Clinical Pharmacology and Therapeutics 26: 63–72 (1979). Donigian, D.W. and Owellen, R.J.: Interaction of vinblastine, vincristine and colchicine with serum proteins. Biochemical Pharmacology 22: 2113–2119 (1973). Erlanger, M.; Martz, G.; Ott, F.; Storck, H.; Rieder, J. and Kessler, S.: Cutaneous absorption and urinary excretion of 6-14C-5-fluorouracil ointment applicated in an ointment to healthy and diseased human skin. Dermatologica 140 (Suppl. 1): 7–14 (1970). Erlichman, C.; Donehower, R.C. and Chabner, B.A.: The practical benefits of pharmacokinetics in the use of antineoplastic agents. Cancer Chemotherapy and Pharmacology 4: 139–145 (1980). Evans, W.E.; Crom, W.R.; Yee, G.C.; Green, A.A.; Hayes, F.A.; Pratt, C.B. and Avery, T.L.: Adriamycin pharmacokinetics in children. Proceedings of the American Association of Cancer Research 21: 176 (1980). Evans, W.E. and Pratt, C.B.: Effect of pleural effusion on high-dose methotrexate kinetics. Clinical Pharmacology and Therapeutics 23: 68–72 (1978). Fenselau, C.; Kan, M-N.N.; Billets, S. and Colvin, M.: Identification of phosphorodiamidic acid mustard as a human metabolite of cyclophosphamide. Cancer Research 35: 1453–1457 (1975). Fenselau, C.; Kan, M-N.N.; Subba Rao, S.; Myles, A.; Friedman, O.M. and Colvin, M.: Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Research 37: 2538–2543 (1977). Finn, C. and Sadee, W.: Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. Cancer Chemotherapy Reports (Part 1) 59: 279–286 (1975). Fraile, R.J.; Baker, L.H.; Buroker, T.R.; Horwitz, J. and Vaitkevicius, V.K.: Pharmacokinetics of 5-fluorouracil adminstered orally, by rapid intravenous and by slow infusion. Cancer Research 40: 2223–2228 (1980). Fulton, D.W.; Levin, V.A.; Gutin, P.H.; Edwards, M.S.; Saeger, M.L. and Wilson, C.B.: Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Treatment Reports (In press, 1981). Gale, R.P.: Advances in the treatment of acute myelogenous leukemia. New England Journal of Medicine 300: 1189–1199 (1979). Garnick, M.B.; Ensminger, W.D. and Israel, M.: A Clinicalpharmacological evaluation of hepatic arterial infusion of adriamycin. Cancer Research 39: 4105–4110 (1979). Gormley, P.E.; Bull, J.M.; LeRoy, A.F. and Cysyk, R.: Kinetics of dis-dichlorodiammineplatinum. Clinical Pharmacology and Therapeutics 25: 351–357 (1979). Gralla, R.J.; Tan, C.T.C. and Young, C.W.: Vindesine, a review of phase II trials. Cancer Chemotherapy and Pharmacology 2: 271–274 (1979). Grochow, L.B. and Colvin, M.: Clinical pharmacokinetics of cyclophosphamide. Clinical Pharmacokinetics 4: 380–394 (1979). Hande, K.; Gay, J.; Gober, J. and Greco, F.A.: Toxicity and pharmacology of bolus vindesine injection and prolonged vindesine infusion. Cancer Treatment Reviews 7 (Suppl.): 25–30 (1980). Harris, P.A. and Gross, J.F.: Preliminary pharmacokinetic models for adriamycin (NSC-123127). Cancer Chemotherapy Reports (Part 1) 59: 819–825 (1975). Hayes, D.M.; Cvitkovic, E.; Golbey, R.B.; Scheiner, E.; Helson, L. and Krakoff, I.H.: High dose cis-platinum diammine dichloride; amelioration of renal toxicity by mannitol diuresis. Cancer 39: 1372–1381 (1977). Henderson, E.S.; Adamson, R.H. and Oliverio, V.T.: The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Research 25: 1018–1024 (1965). Higby, D.J.; Buchholtz, L.; Chary, K.; Avellanosa, A. and Henderson, E.S.: Kinetics of cis-platinum (DDP) with intensive diuresis. Proceedings of the American Association for Cancer Research 18: 110 (1977). Hill, B.T. and Whelan, R.D.H.: Comparative effects of vincristine and vindesine on cell cycle kinetics in vitro. Cancer Treatment Reviews 7 (Suppl.): 5–15 (1980). Hill, D.L.; Kirk, M.C. and Struck, R.F.: Microsomal metabolism of nitrosoureas. Cancer Research 35: 296–301 (1975a). Hill, J.M.; Loeb, E.; MacLellan, A.; Hill, N.O.; Kahn, A. and King, J.J.: Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemotherapy Reports (Part 1) 59: 647–659 (1975b). Hilton, J. and Walker, M.D.: Hydroxylation of l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea. Biochemical Pharmacology 24: 2153–2158 (1975). Himmelstein, K.J.; Patton, T.F.; Belt, R.J.; Taylor, S.; Repta, A.J. and Sternson, L.A.: Clinical kinetics of intact cisplatin and some related species. Clinical Pharmacology and Therapeutics 29: 658–664 (1981). Ho, D.H.W. and Frei, E.: Clinical pharmacology of 1-B-D-ara-binofuranosyl-cytosine. Clinical Pharmacology and Therapeutics 12: 944–954 (1971). Holcenberg, J.S.; Kun, L.E.; Ring, B.J. and Evans, W.E.: Effect of hepatic irradiation on the toxicity and pharmacokinetics of adriamycin in children. International Journal of Radiation Oncology, Biology and Physics (In press, 1981). Howell, S.B., Chu, B.B.F., Wung, W.E.; Metha, B.M. and Mendelsohn, J.: Long-duration intracavity infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. Journal of Clinical Investigation 67: 1161–1170 (1981). Huffman, D.H.; Benjamin, R.S. and Bachur, N.R.: Daunorubicin metabolism in acute nonlymphocytic leukemia. Clinical Pharmacology and Therapeutics 13: 895–905 (1972). Huffman, D.H.; Wan, S.H.; Azarnoff, D.L. and Hoogstraten, B.: Pharmacokinetics of methotrexate. Clinical Phannacology and Therapeutics 14: 572–579 (1973). Isacoff, W.H.; Townsend, C.M.; Eilber, F.R.; Forster, T.; Morten, D.L. and Block, J.B.: High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity. Medical and Pediatric Oncology 2: 319–325 (1976). Jackson, D.V. and Bender, R.A.: The clinical pharmacology of the vinca alkaloids, epipodophylotoxins, and maytansine; in Pinedo (Ed.) Clinical Pharmacology of Anti-Neoplastic Drugs, pp.277–293 (Elsevier North-Holland Biomedical Press Amsterdam 1978). Jackson, D.V. and Bender, R.A.: Cytotoxic thresholds of vincris-tine in a murine and a human leukemia cell line in vitro. Cancer Research 39: 4346–4349 (1979). Jackson, D.V.; Castle, M.C. and Bender, R.A.: Biliary excretion of vincristine. Clinical Pharmacology and Therapeutics 24: 101–107 (1978). Jackson, D.V.; Sethi, V.S.; Spurr, C.L. and McWhorter, J.M.: Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Research 41: 1466–1468 (1981a). Jackson, D.V.; Sethi, V.S.; Spurr, C.L.; White, D.R.; Richards, F.; Stuart, J.J.; Muss, H.B.; Cooper, M.R. and Castle, M.C.: Pharmacokinetics of vincristine infusion. Cancer Treatment Reports 65: 1043–1048 (1981b). Jackson, D.V.; Sethi, V.S.; Spurr, C.L.; Willard, V.; White, D.R.; Richards, F.; Stuart, J.J.; Muss, H.B.; Cooper, M.R.; Homesley, H.D.; Jobson, V.W. and Castle, M.C: Intravenous vincristine infusion. Cancer 48: 2559–2564 (1981c). Jacobs, C.; Kaiman, S.M.; Tretton, M. and Weiner, M.W.: Renal handling of cis-diamminedichloroplatinum (II). Cancer Treatment Reports 64: 1223–1226 (1980). Jacobs, S.A.; Bleyer, W.A.; Chabner, B.A. and Johns, D.G.: Altered plasma pharmacokinetics of methotrexate administered intrathecally. Lancet 1: 455–456 (1975). Jacobs, S.A.; Derr, C.J. and Johns, D.G.: Accumulation of methotrexate diglutamate in human liver during methotrexate therapy. Biochemical Pharmacology 26: 2310–2313 (1977). Jacobs, S.A.; Stoller, R.G.; Chabner, B.A. and Johns, D.G.: 7-Hydroxymethotrexate as a urinary metabolite in human subjects and Rhesus monkeys receiving high dose methotrexate. Journal of Clinical Investigation 57: 534–538 (1976). Jao, J.Y.; Jusko, W.J. and Cohen, J.L.: Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Research 32: 2761–2764 (1972). Jardine, I.; Fenselau, C.; Appier, M.; Kan, M-N.; Brundrett, R.B. and Colvin, M.: Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Research 38: 408–415 (1978). Johns, D.G.; Rutherford, L.D.; Leighton, P.C. and Vogel, C.L.: Secretion of methotrexate into human milk. American Journal of Obstetrics and Gynecology 112: 978–980 (1972). Johnson, I.S.; Armstrong, J.G.; Gorman, M. and Burnett, J.P.: The vinca alkaloids: a new class of oncolytic agents. Cancer Research 23: 1390–1427 (1963). Jones, R.B.; Collins, J.M.; Myers, C.E.; Brooks, A.E.; Hubbard, S.M.; Balow, J.E., Brennan, M.F.; Dedrick, R.L. and DeVita, V.T.: High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Research 41: 55–59 (1981). Juma, F.D.; Rogers, H.J. and Trounce, J.R.: Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. British Journal of Clinical Pharmacology 8: 209–217 (1979). Kahn, A.B.; D’souza, B.; Wharam, M.; Sinks, L.; Woo, S.; McCullough, D. and Leventhal, B.G.: Cisplatinum in recurrent brain tumors. Proceedings of The American Society of Clinical Oncology 22: 402 (1981). Karanes, C.; Wolff, S.N.; Herzig, G.P.; Phillips, G.L.; Lazarus, H.M. and Herzig, R.H.: High dose cytosine arabinoside in the treatment of patients with refractory acute nonlymphocytic leukemia. Blood 54 (Suppl): 191a (1979). Katz, M.E. and Glick, J.H.: Nitrosoureas: A reappraisal of clinical trials. Cancer Clinical Trials 2: 297–316 (1979). Kearney, P.J.; Light, P.A.; Preece, A. and Mott, M.G.: Unpredictable serum levels after oral methotrexate in children with acute lymphocytic leukemia. Cancer Chemotherapy and Pharmacology 3: 117–120 (1979). Kessel, D.; Hall, T.C. and Rosenthal, D.: Uptake and phosphorylation of cytosine arabinoside by normal and leukemia human blood cells in vitro. Cancer Research 29: 459–463 (1969). Kiely, J.M.: Series on pharmacology in practice. 12. Antineoplastic agents. Mayo Clinic Proceedings 56: 384–392 (1981). Kramer, W.G.; Feldman, S.; Broughton, A.; Strong, J.E.; Hall, S.W. and Hoyole, P.Y.: The pharmacokinetics of bleomycin in man. Journal of Clinical Pharmacology 18: 346–352 (1978). Kreis, W.; Woodcock, T.; Tan, C. and Krakoff, I.H.: Physiologic disposition of tetrahydrouridine and its effect upon the deamination of arabinosylcytosine in humans. Proceedings of the American Association for Cancer Research 18: 226 (1977). Krishan, A. and Frei, E.: Morphological basis for the cytolytic effect of vinblastine and vincristine on cultured human leukemia lymphoblasts. Cancer Research 35: 497–501 (1975). Kristensen, L.O.; Weismann, K. and Hutters, L.: Renal function and the rate of disappearance of methotrexate from serum. European Journal of Clinical Pharmacology 8: 439–444 (1975). Lampkin, B.C.; Nagao, T. and Mauer, A.M.: Synchronization and recruitment in acute leukemia. Journal of Clinical Investigation 50: 2204–2214 (1971). Lange, R.C.; Spencer, R.P. and Harder, H.C: The anthumor agent cis-Pt (NH3)2) C12: Distribution studies and dose calculations for 193m-Pt and 193m-Pt. Journal of Nuclear Medicine 14: 191–195 (1973). Lazarus, H.M.; Herzig, R.H.; Herzig, G.P.; Phillips, G.L.; Roessmann, U. and Fishman, D.J.: Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 48: 2577–2582 (1981). Lee, Y-T.N.; Chan, K.K.; Harris, P.A. and Cohen, J.L.: Distribution of adriamycin in cancer patients, tissue uptakes, plasma concentration after IV and hepatic IA administration. Cancer 45: 2231–2239 (1980). Lerne, P.R.; Creaven, P.J.; Allen, L.M. and Berman, M.: Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Cancer Chemotherapy Repons (Part 1) 59: 811–817 (1975). LeRoy, A.F.; Lutz, R.J.; Dedrick, R.L.; Litterst, C.L. and Guar-ino, A.M.: Pharmacokinetic study of cis-dichlorodiammine-platinum (II) (DDP) in the beagle dog: thermodynamic and kinetic behaviour of DDP in a biologic milieu. Cancer Treatment Reports 63: 59–71 (1979). Levin, V.A.; Hoffman, W. and Weinkam, R.J.: Pharmocokinetics of BCNU in man: A preliminary study of 20 patients. Cancer Treatment Reports 62: 1305–1312 (1978). Levin, V.A.; Stearns, J.; Byrd, A., Finn, A. and Weinkam, R.J.: The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis (2-chloroethyl)-l-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-Dioxo-3-piperidyl)-l-nitrosourea(PCNU), and the plasma pharmacokinetics and biotransformation of BCNU. Journal of Pharmacology and Experimental Therapeutics 208: 1–6 (1979). Liegler, D.G.; Henderson, E.S.; Hahn, M.A. and Oliverio, V.T.: The effect of organic acids on renal clearance of methotrexate in man. Clinical Pharmacology and Therapeutics 10: 849–857 (1969). Liiterst, C.L.; LeRoy, A.F. and Guarino, A.M.: Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammine-platinum (II) to animals. Cancer Treatment Reports 63: 1485–1492 (1979). MacMillan, W.E.; Wolberg, W.H. and Welling, P.G.: Pharmacokinetics of fluorouracil in humans. Cancer Research 38: 3479–3482 (1978). Madajewicz, S.; Kanter, P.; West, C.; Bhargava, A.; Prajapati, R.; Caracandas, J.; Avellanosa, A. and Fitzpatrick, J.: Plasma, spinal fluid, and organ distribution of cis-platinum (DDP) following intravenous (IV) and intracarotic (IC) infusion. Proceedings of the American Association for Cancer Research 22: 176 (1981). Madias, N.E. and Harrington, J.T.: Platinum nephrotoxicity. The American Journal of Medicine 65: 307–314 (1978). Mandel, M.A.: The synergistic effect of salicylates on methotrexate toxicity. Plastic and Reconstructive Surgery 57: 733–737 (1976). May, H.E.; Boose, R. and Reed, D.J.: Microsomal monooxygen-ation of the carcinostatic 1-(2-chloroethyI)-3-cyclohexyI-l-ni-trosourea. Synthesis and identification of cis and trans monohydroxylkated products. Biochemistry (Columbus) 14: 4723–4730 (1975). Mellett, L.B.: Considerations in design of optimal therapeutic schedules. Proceedings of the 5th International Congress on Pharmacology 3: 332–353 (1973). Momparler, R.L.: Kinetic and template studies with 1-B-D-ara-binofuranosyl-cytosine 5′-triphosphate and mammalian deoxyribonucleic acid polymerase. Molecular Pharmacology 8: 362–370 (1972). Monjanel, S.; Rigault, J.P.; Cano, J.P.; Carcassonne, Y. and Favre, R.: High-dose methotrexate: Preliminary evaluation of a pharmacokinetic approach. Cancer Chemotherapy and Pharmacology 3: 189–196 (1979). Mouridsen, H.T.; Faber, O. and Skovsted, L.: The biotransformation of cyclophosphamide in man: Analysis of the variation in normal subjects. Acta Pharmacologica et Toxicologica 35: 98–106 (1974). Mouridsen, H.T.; Faber, O. and Skovsted, L.: The metabolism of cyclophosphamide, dose dependency and the effect of longterm treatment with cyclophosphamide. Cancer 37: 665–670 (1976). Mouridsen, H.T. and Jacobsen, E.: Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacologica et Toxicologica 36: 409–414 (1975). Muggia, F.M.; Rozencweig, M. and Penta, J.: Clinical implications of cisplatin pharmacology. Recent Results in Cancer Research 74: 132–138 (1980). Mulder, J.H.; Smink, T. and van Putten, L.M.: 5-Fluorouracil and methotrexate combination chemotherapy: The effect of drug scheduling. European Journal of Cancer and Clinical Oncology 17: 831–837 (1981). Myers, C.E.: The anthracylines; in Pinedo (Ed.) Cancer Chemotherapy Annual (Excerpta Medica, Amsterdam 1979). Myers, C.E.; Diasio, R.; Eliot, H.M. and Chabner, B.A.: Pharmacokinetics of the fluoropyrimidines: Implications for their clinical use. Cancer Treatment Reviews 3: 175–183 (1976). Nelson R.L.; Dyke, R.W. and Root, M.A.: Comparative pharmacokinetics of vindesine, vincristine, and vinblastine in patients with cancer. Cancer Treatment Reviews 7 (Suppl.): 17–24 (1980). Natale, R.B.; Gralla, R.J.; Wittes, R.E.; Golbey, R.B. and Young, C.W.: Vindesine chemotherapy in lung cancer. Cancer Treatment Reviews 7 (Suppl.): 59–63 (1980). Oliff, A.; Bleyer, W.A. and Poplack, D.G.: Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemotherapy and Pharmacology 2: 225–226 (1979). Ostrow, S.; Egorin, M.; Aisner, J.; Bachur, N. and Wiernik, P.H.: High-dose cis-diamminedichloroplatinum therapy in patients with advanced breast cancer: Pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clinical Trials 3: 23–27 (1980). Owellen, R.J. and Hartke, C.A.: The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. Cancer Research 35: 975–980 (1975). Owellen, R.J.; Hartke, C.A.; Dickerson, R.M. and Hains, F.O.: Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class. Cancer Research 36: 1499–1502 (1976). Owellen, R.J.; Hartke, C.A. and Hains, F.O.: Pharmacokinetics and metabolism of vinblastine in humans. Cancer Research 37: 2597–2602 (1977a). Owellen, R.J.; Root, M.A. and Hains, F.O.: Pharmacokinetics of vindesine and vincristine in humans. Cancer Research 37: 2603–2607 (1977b). Patton, T.F.; Himmelstein, K.J.; Belt, R.; Bannister, S.J.; Sternson, L.A. and Repta, A.J.: Plasma levels and urinary excretion of filterable platinum species following bolus injection and IV infusion of cis-dichlorodiammine-platinum (II) in man. Cancer Treatment Reports 62: 1359–1362 (1978). Pierce, R.N. and Jatlow, P.I.: Measurement of adriamycin (doxorubicin) and its metabolites in human plasma using reversed-phase high-performance liquid chromatography and fluorescence detection. J. Chromatog. 164: 471–478 (1979). Pittman, S.W.; Parker, L.M.; Tattersall, M.H.N.; Jaffe, N. and Frei, E.: Clinical trial of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3590)-toxologic and therapeutic observations. Cancer Chemotherapy Reports (Part 3) 6: 43–49 (1975). Pratt, C.B.; Hayes, A.; Green, A.A.; Evans, W.E.; Seuzer, N.; Howarth, C.B.; Ransom, J.L. and Crom, W.: Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: A phase II study. Cancer Treatment Reports 65: 1021–1026 (1981). Pratt, C.B.; Roberts, O.; Shanks, E. and Warmath, E.L.: Response, toxicity and pharmacokinetics of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3590) rescue for children with osteosarcoma and other malignant tumors. Cancer Chemotherapy Reports (Part 3) 6: 13–18 (1975). Pratt, W.B. and Ruddon, R.W.: The Anticancer Drugs (Oxford University Press, Oxford 1979). Prestayko, A.W. and Crooke, S.T.: Clinical pharmacology of bleomycin; in Carter and Cooke (Eds) Bleomycin, Current Status and New Developments, pp. 117–130 (Academic Press New York 1978). Prestayko, A.W.; D’Aoust, J.C.; Issell, B.F. and Crooke, S.T.: Cisplatin (cis-diamminedichloroplatinum II). Cancer Treatment Reviews 6: 17–39 (1979). Prestayko, A.W.; Luft, F.C.; Einhorn, L. and Crooke, S.T.: Cisplatin pharmacokinetics in a patient with renal dysfunction. Rashbaum, S.A. and Cozzarelli, N.R.: Mechanism of DNA synthesis inhibition by arabinosyl cytosine and arabinosyl adenine. Nature 264: 679–680 (1976). Reddel, R.R.; Kefford, R.F.; Grant, J.M.; Coates, A.S.; Fox, R.M. and Tattersall, M.H.N.: Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treatment Reports 66: 19–23 (1982). Reimers, W.A.: The Chemistry of Antitumor Antibiotics, Vol. I, pp. 176–220 (John Wiley and Sons, New York 1979). Rozencweig, M.; Von Hoff, D.D.; Slavik, M. and Muggia, F.M.: Cis-diammine-dichloroplatinum (II): A new anticancer drug. Annals of Internal Medicine 86: 803–812 (1977). Rudnick, S.; Cadman, E.C.; Capizzi, R.L.; Skeel, R.T.; Bertino, J.R. and Mclntosh, S.: High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 44: 1189–1193 (1979). Sadee, W. and Wong, C.G.: Pharmacokinetics of 5-fluorouracil: Inter-relationships with biochemical kinetics in monitoring therapy. Clinical Pharmacokinetics 2: 437–450 (1977). Salmon, S.E.: Cancer chemotherapy; in Meyers et al. (Eds) Review of Medical Pharmacology (7th ed.) pp.477–513 Lange Medical Publications Los Altos, California 1980). Salser, J.S. and Balis, M.E.: Levels of thymidine (TdR) phosphorylase (TP) during TdR and 5-fluorouracil (5-FU) therapy. Proc. Amer. Assoc. Cancer Research 20: 127 (1979). Santi, D.V.; McHenry, C.S. and Sommer, A.: Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13: 471–480 (1974). Schein, P.S.; Heal, J.; Green, D. and Woolley, P.V.: Pharmacology of nitrosourea antitumor agents. Antibiotics and Chemotherapy 23: 64–75 (1978). Sethi, V.S.; Castle, M.C.; Surratt, P.; Jackson, D.V. and Spurr, C.L.: Isolation and partial characterization of human urinary metabolites of vincristine sulphate. Proceedings of the American Association for Cancer Research 22: 173 (1981a). Sethi, V.S.; Jackson, D.V.; White, D.R.; Richards, F.; Stuart, J.J.; Muss, H.B.; Cooper, M.R. and Spurr, C.L.: Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Research 41: 3551–3555 (1981b). Shen, D.D and Azarnoff, D.L.: Clinical pharmacokinetics of methotrexate. Clinical Pharmacokinetics 3: 1–13 (1978). Sitar, D.S.; Shaw, D.H.; Thirwell, M.P. and Reudy, J.R.: Disposition of 5-fluorouracil after intravenous bolus doses of a commercial formulation to cancer patients. Cancer Research 37: 3981–3984 (1977). Sladek, N.E.; Priest, J.; Doeden, D.; Mirocha, C.J.; Pathre, S. and Krivit, W.: Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treatment Reports 64: 1061–1066 (1980). Smith, D.K.; Omura, G.A. and Ostroy, F.: Clinical pharmacology of intermediate-dose oral methotrexate. Cancer Chemotherapy and Pharmacology 4: 117–120 (1980). Smith, P.H.S. and Taylor, D.M.: Distribution and retention of the antitumor agent 195m-Pt-cis-dichlorodiammine platinum (II) in man. Journal of Nuclear Medicine 15: 349–351 (1974). Sponzo R.W.; DeVita, V.T. and Oliverio, V.T.: Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1 -nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU) in man. Cancer 31: 1154–1159 (1973). Stambaugh, J.E.: Phase II trial of vindesine in advanced neoplastic disease. Cancer Treatment Reviews 7 (Suppl.): 75–79 (1980). Steele, W.H.; Stuart, J.F.B.; Whiting, B.; Lawrence, J.R.; Caiman, K.C.; McVie, J.G. and Baird, G.M.: Serum, tear and salivary concentrations of methotrexate in man. British Journal of Clinical Pharmacology 207–211 (1979a). Steele, W.H.; Lawrence, J.R.; Stuart, J.F.B. and McNeill, C.A.: The protein binding of methotrexate by the serum of normal subjects. Europ. J. Clin. Pharmacol. 15: 363–366 (1979b). Stewart, D.J.; Leavens, M.; Luna, M.; Seifert, W.; Loo, T.L. and Benjamin, R.S.: Human central nervous system pharmacology of cis-diamminedichloroplatinum (DDP). Proceedings of the American Society of Clinical Oncology 22: 359 (1981). Stoller, R.G.; Hande, K.R.; Jacobs, S.A.; Rosenberg, S.A. and Chabner, B.A.: Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New England Journal of Medicine 297: 630–634 (1977). Stoller, R.G.; Jacobs, S.A.; Drake, J.C.; Lutz, R.J. and Chabner, B.A.: Pharmacokinetics of high-dose methotrexate (NSC-740). Cancer Chemotherapy Reports (Part 3) 6: 19–24 (1975). Struck, R.F.; Kirk, M.C.; Mellen, L.B.; El Dareer, S. and Hill, D.L.: Urinary metabolites of the antitumor agent cyclophosphamide. Molecular Pharmacology 7: 519–529 (1971). Takahashi, S. and Bachur, N.R.: Adriamycin metabolism in man, evidence from urinary metabolites. Drug Metabolism and Disposition 4: 79–87 (1976). Tattersall, M.H.N.; Jackson, R.C.; Connors, T.A. and Harrup, K.R.: Combination chemotherapy interaction of methotrexate and 5-fluorouracil. European Journal of Cancer 9: 733–739 (1973). Taylor, J.R. and Halprin, K.M.: Effect of sodium salicylate and indomethacin on methotrexate-serum albumin binding. Archives of Dermatology 113: 588–591 (1977). Ullman, B.; Lee, M.; Martin, D.W. and Santi, D.V.: Cytotoxicity of 5-fluoro-2-deoxyuridine: Requirement for reduced folate cofactors and antagonism by methotrexate. Proceedings of the National Academy of Sciences 75: 980–983 (1978). Umezawa, H.: Recent studies on biochemistry and action of bleomycin, in Carter and Cooke (Eds) Bleomycin, Current Status and New Developments, pp. 15–19 (Academic Press, New York (1978). Valdivieso, M.: Phase I and II studies of vindesine. Cancer Treatment Reviews 7 (Suppl.): 31–37 (1980). van Prooijen, R.; van der Kjeijn, E. and Haanen, C.: Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia. Clinical Pharmacology and Therapeutics 21: 744–750 (1977). Walker, M.D. and Hilton, J.: Nitrosourea pharmacodynamics in relation to the central nervous system. Cancer Treatment Reports 60: 725–728 (1976). Wan, S.H.; Huffman, D.H.; Azarnoff, D.L.; Hoogstraten, B. and Larsen, W.E.: Pharmacokinetics of 1-B-D-arabinofuranosylcytosine in humans. Cancer Research 34: 392–397 (1974a). Wan, S.H.; Huffman, D.H.; Azarnoff, D.L.; Stephens, R. and Hoogstraten, B.: Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Research 34: 3487–3491 (1974b). Wang, Y-M.; Lantin, E. and Sutow, W.W.: Methotrexate in blood, urine and cerebrospinal fluid of children receiving high doses by infusion. Clinical Chemistry 22: 1053–1056 (1976). Wang, L.H.; Lee, C.S.; Majeske, B.L. and Marbury, T.C.: Clearance and recovery calculations in hemodialysis: Application to plasma, red blood cell and dialysate measurements for cydophosphamide. Clinical Pharmacology and Therapeutics 29: 365–372 (1981). Wasserman, T.H.: The nitrosoureas: An outline of clinical schedules and toxic effects. Cancer Treatment Reports 60: 709–711 (1976). Wasserman, T.H.; Slavik, M. and Carter, S.K.: Review of CCNU in clinical cancer therapy. Cancer Treatment Reviews 1: 131–151 (1974a). Wasserman, T.H.; Slavik, M. and Carter, S.K.: Methyl-CCNU in clinical cancer therapy. Cancer Treatment Reviews 1: 251–269 (1974b). Weber, W.; Nagel, G.A.; Nagel-Studer, E. and Albrecht, R.: Vincristine infusion — a phase I study. Cancer Chemotherapy and Pharmacology 3: 49–55 (1979). West, G.W.; Weichselbaum, R. and Little, J.B.: Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Research 40: 3665–3668 (1980). Wheeler, G.P.; Johnston, T.P.; Bowdon, B.J.; McCaleb, G.S.; Hill, D.L. and Montgomery, J.A.: Comparison of the properties of metabolites of CCNU. Biochemical Pharmacology 26: 2331–2336 (1977). Wilkinson, P.M.; Israel, M.; Pegg, W.J. and Frei, E.: Comparative metabolism and excretion of adriamycin in man, monkey and rat. Cancer Chemoth. Pharmacol. 2: 121–125 (1979). Williams, C.J.; Stevenson, K.E. and Whitehouse, J.M.A.: Pharmacokinetics and toxicity of cis-diamminedichloroplatinum (DDP) given by IV bolus, 24 or 48 hour infusion. Proceedings of the American Society of Clinical Oncology 20: 317 (1979). Williams, C.J. and Whitehouse, J.M.A.: Cis-platinum: A new anticancer agent. British Medical Journal 1: 1689–1691 (1979). Witten, J.; Frederiksen, P.L. and Mouridsen, H.T.: The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol. Acta Pharm. Toxicol. 46: 392–394 (1980). Young, R.L.; Ozols, R.F. and Myers, C.E.: The anthracycline antineoplastic drugs. New England Journal of Medicine 305: 139–153 (1981). Zeffren, J.; Yagod, A.; Kelsen, D. and Winn, R.: Phase I trial of a 5-day infusion of vinblastine. Proceedings of the American Association for Cancer Research 21: 178 (1980). Zwelling, L.A. and Kohn, K.W.: Mechanism of action of cis-dich-lorodiammineplatinum (II). Cancer Treatment Reports 63: 1439–1444 (1979).